Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Korro Bio, Inc. (KRRO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on Nasdaq. Korro focuses on RNA-editing genetic medicines, and its filings with the U.S. Securities and Exchange Commission offer detailed information on clinical programs, collaborations, restructuring actions, and executive changes that complement its press releases.
Investors can review Forms 10-K and 10-Q for narrative and financial discussion of Korro’s development of KRRO-110 for Alpha-1 Antitrypsin Deficiency, the REWRITE Phase 1/2a clinical trial design, and the OPERA RNA editing platform. These periodic reports also describe risk factors, research and development spending, and collaboration revenue, including from its research collaboration and license agreement with Novo Nordisk A/S.
Current reports on Form 8-K are particularly relevant for tracking material events at Korro. Recent 8-K filings describe the amendment to the Novo Nordisk collaboration establishing a 12‑month pause in research and development activities, strategic restructuring and workforce reductions intended to extend cash runway, and executive transitions such as the resignation of the Chief Financial Officer and Chief Medical Officer and related separation agreements. Other 8-Ks outline compensatory arrangements, including amended employment agreements and equity awards.
Users can also monitor proxy statements and compensation disclosures referenced in Korro’s 8-Ks for background on executive employment terms, as well as any Form 4 insider transaction reports that may be filed to reflect equity grants or option exercises under the company’s stock plans. Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, highlight important sections of long reports, and help readers quickly understand how new filings may relate to Korro’s RNA-editing pipeline, collaborations, and capital allocation.
Korro Bio, Inc. reported that investment entities associated with Rick Yang made significant indirect open-market purchases of its securities. On March 10, 2026, New Enterprise Associates 17, L.P. acquired 242,945 Pre-Funded Warrants at $11.1090 per warrant and 207,100 shares of Common Stock at $11.1100 per share under a Subscription Agreement dated March 9, 2026. Following these transactions, NEA 17 indirectly holds 1,297,893 shares of Common Stock and the Pre-Funded Warrants, while the Reporting Person disclaims beneficial ownership where there is no pecuniary interest. The Pre-Funded Warrants are exercisable at any time, subject to a 9.99% ownership cap that can be adjusted up to 19.99% with 61 days’ prior notice.
SANDELL SCOTT D reported open-market purchase transactions in this Form 4 filing.
Korro Bio, Inc. insider entities linked to Scott D. Sandell indirectly acquired 242,945 Pre-Funded Warrants and 207,100 shares of Common Stock on March 10, 2026, pursuant to a Subscription Agreement dated March 9, 2026.
The Pre-Funded Warrants carry a $0.001 exercise price and are exercisable at any time, subject to a 9.99% ownership cap that can be adjusted up to 19.99% with 61 days’ notice.
New Enterprise Associates 17, L.P., a 10% owner of Korro Bio, Inc., bought additional securities in the company. On March 10, 2026, it acquired 207,100 shares of Common Stock at $11.11 per share and 242,945 Pre-Funded Warrants at $11.109 per warrant pursuant to a Subscription Agreement dated March 9, 2026.
The Pre-Funded Warrants are exercisable at $0.001 per share at any time after issuance but include a beneficial ownership cap that generally limits the holder to 9.99% of Korro Bio’s outstanding Common Stock, which can be adjusted up to 19.99% with 61 days’ prior notice.
Korro Bio, Inc. reported that a 10% owner associated with Carmen Chang made significant indirect open-market purchases of its securities. On March 10, 2026, an entity affiliated with her acquired 242,945 Pre-Funded Warrants at $11.109 per warrant and 207,100 shares of Common Stock at $11.11 per share, totaling 450,045 securities.
The Pre-Funded Warrants were acquired from the company under a Subscription Agreement dated March 9, 2026 and are exercisable at any time, subject to a beneficial ownership cap of 9.99% of outstanding common stock, adjustable up to 19.99% with 61 days’ notice. The transactions are reported as indirect holdings through New Enterprise Associates 17, L.P., and Chang disclaims beneficial ownership of any portion in which she has no pecuniary interest.
Korro Bio, Inc. reported that investment entities associated with director and 10% owner Ali Behbahani acquired additional securities. On March 10, 2026, NEA 17 received 242,945 Pre-Funded Warrants, each exercisable into one share of Common Stock at $0.001 per share, subject to a 9.99% ownership cap that can be raised up to 19.99% with 61 days’ notice. The same day, NEA 17 was also awarded 207,100 shares of Common Stock at $11.11 per share, bringing its indirectly held Common Stock position to 1,297,893 shares. Behbahani is a manager of the NEA 17 general partners and disclaims beneficial ownership of portions in which he has no pecuniary interest.
Korro Bio, Inc. reported that investment entity New Enterprise Associates 17, L.P. acquired additional exposure to its stock through a private subscription. On March 10, 2026, it bought 207,100 shares of common stock at $11.11 per share and 242,945 pre-funded warrants at $11.109 per warrant. The warrants are exercisable at $0.001 per share but include a 9.99% beneficial ownership cap, which the holder may adjust upon 61 days’ notice, not to exceed 19.99%. Following these purchases, indirect holdings include 1,297,893 shares of common stock and the newly acquired warrants. Forest Baskett is a manager of entities controlling NEA 17 and disclaims beneficial ownership where he has no pecuniary interest.
Korro Bio, Inc. reported that an entity associated with major holder Edward T. Mathers bought additional securities. On March 10, 2026, New Enterprise Associates 17, L.P., for which Mathers is an affiliated manager, acquired 242,945 Pre-Funded Warrants at $11.109 per underlying share and 207,100 shares of Common Stock at $11.110 per share in a purchase coded as an open-market transaction and documented in a Subscription Agreement dated March 9, 2026.
The Pre-Funded Warrants are immediately exercisable at an exercise price of $0.001 per share but contain a Beneficial Ownership Limitation that generally caps the holder’s ownership at 9.99% of Korro Bio’s outstanding Common Stock after exercise, with the cap adjustable on 61 days’ notice up to 19.99%. Following these transactions, indirect holdings reported for Common Stock totaled 1,297,893 shares.
Korro Bio, Inc. reported insider-related purchases of both common stock and pre-funded warrants by an entity associated with major holder Mohamad Makhzoumi. On March 10, 2026, New Enterprise Associates 17, L.P. acquired 242,945 pre-funded warrants at $11.1090 per underlying share and 207,100 shares of common stock at $11.1100 per share in open-market or private transactions pursuant to a Subscription Agreement dated March 9, 2026. The pre-funded warrants are exercisable at $0.0010 per share and include a beneficial ownership cap of 9.99%, which the holder may adjust to as high as 19.99% with 61 days’ prior notice.
Korro Bio, Inc. insider Paul Edward Walker, a reported ten percent owner through New Enterprise Associates entities, reported net purchases of Korro Bio securities. An affiliate bought 242,945 Pre-Funded Warrants, each exercisable into one share of Common Stock at an exercise price of $0.001 per share, at a purchase price of $11.109 per warrant.
The same affiliated fund also bought 207,100 shares of Common Stock at $11.11 per share, bringing its indirect Common Stock holdings to 1,297,893 shares following the transactions. All securities are held indirectly by New Enterprise Associates 17, L.P., and Walker disclaims beneficial ownership of any portion in which he has no pecuniary interest.
The Pre-Funded Warrants are immediately exercisable but include a beneficial ownership limitation: they cannot be exercised if doing so would cause the holder and certain related parties to exceed 9.99% of Korro Bio’s outstanding Common Stock, a cap that can be adjusted up to 19.99% with 61 days’ prior notice.
Florence Anthony A. Jr. reported open-market purchase transactions in this Form 4 filing.
Korro Bio, Inc. disclosed that investment fund New Enterprise Associates 17, L.P. (NEA 17), an entity associated with 10% owner Anthony A. Florence Jr., entered into a Subscription Agreement with the company. On March 10, 2026, NEA 17 acquired 242,945 Pre-Funded Warrants at $11.109 per underlying share and 207,100 shares of Common Stock at $11.11 per share. Following the transaction, NEA 17 held 242,945 pre-funded warrants (each exercisable into one share of Common Stock at $0.001 per share) and 1,297,893 shares of Common Stock. The pre-funded warrants are exercisable at any time but include a 9.99% beneficial ownership cap, which the holder may adjust upon 61 days' notice, not to exceed 19.99%. Florence is a manager of the NEA 17 general partner and disclaims beneficial ownership of portions of these securities in which he has no pecuniary interest.